Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
For high‐risk CINSARC patients, this is a multicenter randomized two‐arm phase III trial, with a ratio 1:1: ‐ Arm A: standard management (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/‐ radiotherapy) ‐ Arm B: experimental arm (6 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/‐ radiotherapy) For low‐risk CINSARC patients, this a multicenter prospective cohort with treatment at the discretion of the investigator.
Epistemonikos ID: 705f7273e3ed9e126461e7bae1a7739ceb19b8a5
First added on: May 21, 2024